• Explore /
  • Poster
  • / Mefatinib as first-line treatment of patients with advanced non–small cell lung cancer harboring rare EGFR mutations.

Mefatinib as first-line treatment of patients with advanced non–small cell lung cancer harboring rare EGFR mutations.

Abstract Poster

Authors

null

Pingli Wang

Department of Respiratory Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China

Pingli Wang , Liming Cao , Panwen Tian , Shengxiang Ren , Liyun Miao , Chengzhi Zhou , Yun Fan , Yuping Li , Dongqing Lv , Xin Zhao , Mei Yang , Chaonan Zhu , June Xu , Yong Song , Kai Wang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

CTR20190110

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 9102)

DOI

10.1200/JCO.2022.40.16_suppl.9102

Abstract #

9102

Poster Bd #

89

Abstract Disclosures

Similar Posters

First Author: Fengying Wu

First Author: Atsushi Nakamura

First Author: Yuangyuan Zhao

First Author: Harry J.M. Groen